A Phase I Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of SC-101 in Subjects With Advanced or Metastatic Solid Tumors That Express Nectin-4
Latest Information Update: 14 Apr 2025
At a glance
- Drugs SC 101 Tianjin ConjuStar Biologics (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Tianjin ConjuStar Biologics
- 09 Apr 2025 Planned End Date changed from 1 Dec 2025 to 1 Sep 2026.
- 09 Apr 2025 Planned primary completion date changed from 1 Jun 2025 to 1 Mar 2026.
- 28 Feb 2024 Status changed from not yet recruiting to recruiting.